Validation of Fluorescence In Situ Hybridization Using an Analyte-Specific Reagent for Detection of Abnormalities Involving the Mixed Lineage Leukemia Gene

被引:12
作者
Saxe, Debra F. [1 ]
Persons, Diane L. [2 ]
Wolff, Daynna J. [3 ]
Theil, Karl S. [4 ]
机构
[1] Emory Univ Hosp, Dept Pathol & Lab Med, Emory Sch Med, Atlanta, GA 30022 USA
[2] Univ Kansas, Dept Pathol & Lab Med, Med Ctr, Kansas City, KS USA
[3] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC USA
[4] Cleveland Clin, Dept Clin Pathol, Cleveland, OH 44106 USA
关键词
11Q23; REARRANGEMENTS;
D O I
10.5858/arpa.2010-0645-SA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Fluorescence in situ hybridization (FISH) is a molecular cytogenetic assay that is commonly used in laboratory medicine. Most FISH assays are not approved by the US Food and Drug Administration but instead are laboratory-developed tests that use analyte-specific reagents. Although several guidelines exist for validation of FISH assays, few specific examples of FISH test validations are available in the literature. Objective.-To provide an example of how a FISH assay, using an analyte-specific reagent probe, may be validated in a clinical laboratory. Design.-We describe the approach used by an individual laboratory for validation of a FISH assay for mixed lineage leukemia (MLL) gene. Results.-Specific validation data are provided illustrating how initial assay performance characteristics in a FISH assay for MLL may be established. Conclusions.-Protocols for initial validation of FISH assays may vary between laboratories. However, all laboratories must establish several defined performance specifications prior to implementation of FISH assays for clinical use. We describe an approach used for assessing performance specifications and validation of an analyte-specific reagent FISH assay using probes for MLL rearrangement in interphase nuclei. (Arch Pathol Lab Med. 2012; 136: 47-52; doi: 10.5858/arpa.2010-0645-SA)
引用
收藏
页码:47 / 52
页数:6
相关论文
共 20 条
[1]  
[Anonymous], 1992, FED REG
[2]  
[Anonymous], 2005, NAT METHODS, V2, P237
[3]  
[Anonymous], 2000, Genetics In Medicine, V2, P356, DOI DOI 10.1097/00125817-200011000-00011
[4]  
Barch MJ, 1997, AGT CYTOGENETICS LAB, P557
[5]   MOLECULAR-BASIS OF 11Q23 REARRANGEMENTS IN HEMATOPOIETIC MALIGNANT PROLIFERATIONS [J].
BERNARD, OA ;
BERGER, R .
GENES CHROMOSOMES & CANCER, 1995, 13 (02) :75-85
[6]   Statistical Treatment of Fluorescence in Situ Hybridization Validation Data to Generate Normal Reference Ranges Using Excel Functions [J].
Ciolino, Allison L. ;
Tang, Mary E. ;
Bryant, Ron .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2009, 11 (04) :330-333
[7]  
Clinical and Laboratory Standards Institute (CLSI), 2006, US VER PERF PREC TRU
[8]   Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization [J].
Cohen, N ;
Novikov, I ;
Hardan, I ;
Esa, A ;
Brok-Simoni, F ;
Amariglio, N ;
Rechavi, G ;
Ben-Bassat, I ;
Trakhtenbrot, L .
CANCER GENETICS AND CYTOGENETICS, 2000, 123 (02) :102-108
[9]  
Commission on Laboratory Accreditation, 2009, LAB ACCR PROGR CYT C
[10]  
Jennings L, 2009, ARCH PATHOL LAB MED, V133, P743, DOI 10.1043/1543-2165-133.5.743